- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04611373
Clinical Study on the Efficacy of Acetazolamide Combined With Levamisole in the Treatment of HCC
October 28, 2020 updated by: Zujiang YU, The First Affiliated Hospital of Zhengzhou University
A Single-center, Single-arm, Open, Prospective, and Exploratory Clinical Study on the Efficacy of Acetazolamide Combined With Levamisole in the Treatment of Advanced HCC
The purpose of this study is to evaluate the efficacy and safety of acetazolamide combined with levamisole in the treatment of advanced HCC.
Study Overview
Detailed Description
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the second leading cause of cancer-related deaths in the world.
Because HCC is insidious and early diagnosis is difficult, most patients have locally advanced or distant metastasis at the time of diagnosis.
So they are not suitable candidates for curative treatments by resection or transplantation.
Currently, There are only not more than five drugs to be selected for advanced HCC, although it prolongs the survival for less than 3 months.
Recently, metabolomics studies of HCC have shown that typical Warburg effect was observed in hepatoma carcinoma cells.
Arginine hydrochloride is a new anticancer drug in the treatment of HCC, which is mainly aimed at the pathway of energy metabolism.acetazolamide
may play an anti-tumor role by inhibiting the reverse TCA cycle.
The investigators have been proceeding this trial to evaluate the efficacy and safety of acetazolamide combined with levamisole in the treatment of advanced HCC.
Study Type
Interventional
Enrollment (Anticipated)
50
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Henan
-
Zhengzhou, Henan, China, 450000
- Recruiting
- the First Affiliated Hospital of Zhengzhou University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Ages 18-65 years
- The diagnosis of ICC: in accordance with "diagnostic and treating standards on primary liver cancer" or histological/cytological diagnosis of primary liver cancer
- Un-resectable HCC : patients with developing primary liver cancer of Barcelona stage(BCLC) B; multiple nodules (less than 5, the total diameter of less than 20 cm), no invasion, no symptoms;refusing open surgical treatment and volunteering for the treatment
- The First-line system therapy failure (or residual lesion) from the group of this study a signed informed consent (time) for 2 weeks or more basic returned to normal and adverse events (NCI CTCAE Ⅰ level or less);
- Child-Pugh liver function class A/B(score: ≤7)
- Performance status 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale in one week before admission
- Estimated survival time > 3 months
- HBV DNA#2000 IU/ml#10^4 copies/ml); or HBV DNA≥2000 IU/ml and are accepting effective antiviral therapy
The major organ function is normal. that is meeting the following standards:
Blood routine examination: (No blood transfusion, no G-CSF and no medication were corrected within 14 days before screening)
- For women of childbearing age, the results of serum/urine pregnancy tests must be negative within 7 days before initiation of treatment. All men and women who participate in the study have to take reliable contraceptive measures within the trial and eight weeks after the trial is completed
- volunteers must signed informed consent
Exclusion Criteria:
- With a history of alimentary tract hemorrhage or a definite tendency of gastrointestinal bleeding, such as varices of fundus of stomach and esophagus with bleeding risk; local active ulcer lesions; fecal occult blood ≥#++#
- Patients with hepatobiliary cell carcinoma, mixed cell carcinoma or lamellar cell carcinoma; in the past (within 5 years) or at the same time suffering from other untreated malignant tumors; excluding cured basal cell carcinoma and carcinoma in situs of cervix
- Patients who are undergoing liver transplantation or have a history of organ transplantation(excluding the patient who has undergone liver transplantation before)
- Patients with an allergic history of Levamisole Hydrochloride and Anlotinib Hydrochloride Capsules
- The blood pressure can not be reduced to the normal range by the antihypertensive drug treatment in patients with hypertension(systolic pressure#140 mmHg, diastolic pressure#90 mmHg)
- Patients with myocardial ischemia or myocardial infarction over grade II or a poorly controlled arrhythmia (including QTc interval: men ≥ 450 ms; women ≥ 470 ms)
- Cardiac functional insufficiency of grade III to IV according to NYHA standard; echocardiography: LVEF#50%
- Many factors that influence oral medication, such as unable to swallow; chronic diarrhea; intestinal obstruction; the situations which significantly affect the use and absorption of drugs
- Abdominal fistula, gastrointestinal perforation, or abdominal abscess occurred within 28 days before participating the study
- Dysfunction of blood coagulation(INR#2.0 or PT# 16s#APTT > 43s#TT > 21s#Fbg < 2g/L), having a tendency to bleed or undergoing thrombolysis or anticoagulant therapy; ascites with clinical symptoms, that is requiring therapeutic abdominal paracentesis or drainage or Child-Pugh score ≥2
- Objective evidence of pulmonary fibrosis history, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug associated pneumonia, and severe lung function impairment in the past and at present
- Urine routine showed that urine protein ≥++ or the urine protein in 24 hours#1.0 g
- Patients who have been treated with potent CYP3A4 inhibitors (ketoconazole, itraconazole, voriconazole, ritonavir, clarithromycin, telithromycin, troleandomycin, erythromycin, cimetidine and so on) within 28 days before participating the study, or potent CYP3A4 inducers (dexamethasone, phenytoin, rifampin, rifabutin, carbamazepine, phenobarbitone and so on) within 12 days before participating the study.
- Pregnant or lactating women; fertile patients who are unwilling or unable to adopt effective contraceptives
- Patients with mental sickness or the history of psychotropic drug abuse
- Patients with severe infection (unable to control the infection effectively)
- The treatment history affecting this program or its efficacy, such as stem cell transplantation, immune regulation (including PD-1 and other test regimens) recently (within half a year)
- The researchers believe that any other factors unsuitable for entering into the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: A
Acetazolamide tablet 25mg/ tablet, 2 tablets a day; Levamisole 25mg/ tablet, 6 tablets/day continuous medication; Continue treatment until the disease progresses
|
Acetazolamide tablet 25mg/ tablet, 2 tablets a day Levamisole 25mg/ tablet, 6 tablets/day Continue treatment until the disease progresses
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free Survival
Time Frame: 24 months
|
Time from start of treatment until the first documented event of symptomatic progression or death
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Surviva
Time Frame: 48 months
|
ime from start of treatment to death from any cause, or last known date of survival
|
48 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate(ORR)
Time Frame: 28 days
|
Proportion of patients with reduction in tumor burden of a predefined amount
|
28 days
|
Disease Control Rate(DCR)
Time Frame: 28 days
|
the percentage of patients with advanced or metastatic cancer who have achieved complete response, partial response and stable disease
|
28 days
|
The change of AFP biomarker
Time Frame: 28 days
|
Concentration of AFP biomarker change in tumor markers
|
28 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
May 1, 2020
Primary Completion (ANTICIPATED)
December 1, 2020
Study Completion (ANTICIPATED)
May 31, 2021
Study Registration Dates
First Submitted
October 28, 2020
First Submitted That Met QC Criteria
October 28, 2020
First Posted (ACTUAL)
November 2, 2020
Study Record Updates
Last Update Posted (ACTUAL)
November 2, 2020
Last Update Submitted That Met QC Criteria
October 28, 2020
Last Verified
October 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Immunologic Factors
- Carbonic Anhydrase Inhibitors
- Natriuretic Agents
- Diuretics
- Adjuvants, Immunologic
- Anticonvulsants
- Antiparasitic Agents
- Antinematodal Agents
- Anthelmintics
- Acetazolamide
- Levamisole
Other Study ID Numbers
- CJVICC-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HCC
-
University of PisaAzienda Ospedaliera Città della Salute e della Scienza di Torino; Fondazione... and other collaboratorsRecruiting
-
Seoul National University HospitalPhilips HealthcareCompleted
-
Huazhong University of Science and TechnologyUnknown
-
Taipei Medical University WanFang HospitalTerminated
-
Leiden University Medical CenterMedtronic; ZonMw: The Netherlands Organisation for Health Research and Development and other collaboratorsCompletedHCC | Early Stage HCCNetherlands
-
Qianfoshan HospitalNot yet recruiting
-
Xuhua DuanRecruiting
-
Ain Shams UniversityCompleted
-
Shenyang Tenth People's HospitalBeijing Tsinghua Changgeng HospitalNot yet recruiting
Clinical Trials on Acetazolamide Levamisole
-
Programme National de Lutte contre l'Onchocercose...Institut de Recherche pour le DeveloppementNot yet recruiting
-
The First Affiliated Hospital of Zhengzhou UniversityFirst Affiliated Hospital of Xinjiang Medical University; Anyang Tumor Hospital and other collaboratorsRecruiting
-
Assistance Publique - Hôpitaux de ParisCompletedFirst Manifestation of Steroid Sensitive Nephrotic SyndromeFrance
-
Asan Medical CenterUnknownVentilator Weaning | Alkalosis, MetabolicKorea, Republic of
-
Ain Shams UniversityUnknownCoronavirus Disease (COVID-19)Egypt
-
University of UtahCompletedProphylaxis of Acute Mountain SicknessUnited States
-
Shengyun LinUnknown
-
The First Affiliated Hospital of Zhengzhou UniversityAnyang Tumor Hospital; Luoyang Central Hospital; Nanyang Central Hospital; Sanmenxia... and other collaboratorsRecruiting
-
US Department of Veterans AffairsWithdrawnStroke | Sleep Apnea, Obstructive
-
Association pour la Recherche en Physiologie de...Universidad Peruana Cayetano Heredia; University of Paris 13; Legs PoixCompleted